Area of research
Hematology · Cognitive Neuroscience
Research interest
Research focused on Placebo and Eltrombopag, with related work in Immune thrombocytopenia, Post-hoc analysis, Clinical endpoint. Notable publications include 'A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy', 'A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia', and 'Transcriptional level of inflammation markers associates with short-term brain structural changes in first-episode schizophrenia'.
Hetrombopag for patients with persistent primary immune thrombocytopenia: a post hoc analysis of a multicenter, randomized phase Ⅲ trial
Hetrombopag for patients with persistent primary immune thrombocytopenia: A post-hoc analysis of a multicenter, randomized phase Ⅲ Trial
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial
The long‐term intake of milk fat does not significantly increase the blood lipid burden in normal and high‐fat diet‐fed mice
Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China
Transcriptional level of inflammation markers associates with short-term brain structural changes in first-episode schizophrenia
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia
Dose tapering to withdrawal stage and long‐term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open‐label extension study
A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy
A Multicenter Open-Labeled Pilot Study on Recombinant Human Thrombopoietin in the Management of Immune Thrombocytopenia in Pregnancy